Cancer-hunting antibodies coupled with a natural compound found in soil microbes proved a powerful combination against an aggressive type of blood cancer, according to a new study from scientists at ...

Lynozyfic (linvoseltamab) has been given accelerated approval by the US regulator for adults with relapsed or refractory ...

Regeneron Pharmaceuticals has won FDA accelerated approval of its Lynozyfic treatment for certain patients with the blood ...

Regeneron Pharmaceuticals said on Wednesday the U.S. Food and Drug Administration has approved its drug for a type of blood ...

Akeso, Inc. (9926.HK) ('Akeso' or the 'Company') has announced the successful enrollment of the first patient in its Phase Ia clinical trial for AK146D1, a bispecific Antibody-Drug Conjugate (ADC) ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Lynozyfic™ (linvoseltamab-gcpt) to treat adult ...

Jacobio Pharma (1167.HK) announced that it has submitted the Phase I/II Investigational New Drug (IND) application for its BET inhibitor JAB-8263 for the treatment of autoimmune diseases to the Center ...

The new vaccine committee appointed by Secretary Robert F. Kennedy Jr. took minimal action in its first meeting.

Lynozyflic is one of two bispecific antibodies Regeneron hopes will lift its oncology business. Meanwhile, IGM is the latest struggling biotech to agree to a buyout deal from Concentra.

This approval comes almost a year after the drug received a complete response letter due to third-party manufacturing issues.

From cancer immunotherapy to diabetes and weight loss breakthroughs, 2025’s top-selling drugs highlight how pharmaceutical ...

The FDA granted accelerated approval of linvoseltamab-gcpt for certain patients with multiple myeloma.Specifically, the ...